The National Biosafety Authority (NBA) has issued a formal directive mandating stringent clearance protocols for all genetically modified organism (GMO) imports entering Kenya. This policy, which takes effect immediately, requires importers to obtain explicit authorization from the NBA prior to the release of any GMO products into the domestic market.
This directive, articulated by NBA Acting Chief Executive Officer Ann Karimi, encompasses a broad spectrum of products, including genetically modified plants, animals, microorganisms, and veterinary vaccines. The initiative is intended to ensure rigorous adherence to the Biosafety Act of 2009, the foundational legislation governing the development, handling, and transboundary movement of GMOs within the country.
To facilitate the effective implementation of this mandate, the NBA has engaged key state agencies, including the Kenya Revenue Authority (KRA) and the Kenya Plant Health Inspectorate Service (KEPHIS). These agencies, which maintain oversight at all national points of entry and exit, are now tasked with verifying that all GMO-related shipments undergo mandatory authentication by the NBA.
“Given the global trade volume of these products, the Authority has systematically profiled the relevant Harmonized System (HS) codes to streamline identification,” Dr. Karimi stated. “We have requested the full cooperation of port and border officials to ensure that all such products receive requisite NBA clearance prior to release.”
To ensure operational compliance, the NBA has deployed specialized personnel to major border points. These officers are mandated to provide regulatory guidance to importers and to facilitate the resolution of non-compliance issues as they arise.
The Biosafety Act of 2009 established the NBA as the primary regulatory authority responsible for conducting comprehensive scientific risk assessments. Its dual objective is to foster safe biotechnological innovation while ensuring the protection of human, animal, and environmental health.
This intensified focus on border oversight underscores Kenya’s commitment to maintaining high biosafety standards. As a signatory to the Cartagena Protocol on Biosafety, Kenya continues to enforce robust regulations concerning the contained use, intentional release, and international trade of GMO commodities.
Kenya’s proactive stance on import regulation coincides with the increasing integration of modified crops into international agricultural supply chains. Domestically, the successful commercialization of Bt cotton—introduced in 2020—serves as a benchmark for the safe application of biotechnology. Globally, Bt-modified crops are widely deployed in major agricultural economies, including the United States, Brazil, India, and South Africa, as well as various jurisdictions within the European Union and Southeast Asia.
While the government views modern biotechnology as a strategic tool for addressing climate-induced food insecurity and pest resilience, the NBA maintains its role as a vigilant regulator. By mandating systematic verification for every shipment, the Authority seeks to mitigate potential risks and preserve public confidence in the integrity of Kenya’s food and agricultural supply chains. Through continued collaboration with regional partners, the NBA is reinforcing a sophisticated framework for the governance of biotechnology across the African continent.
